evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

14 questions · 15 findings · 8 reviews · Vascular

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 13.3%GRADE not reported 5 · 33.3%Very low 1 · 6.7%Low 6 · 40%Moderate 1 · 6.7%High 0 · 0%

Direct thrombin inhibitors vs low molecular weight heparin

All‐cause Mortality events · patients with prevention of venous thromboembolism following total hip or knee replacement

Direct thrombin inhibitors probably leads to higher all‐cause Mortality events compared with low molecular weight heparins (moderate certainty).

1 finding from 1 review

Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (short term)

All‐cause mortality · people who underwent a lower limb revascularisation

Duplex ultrasound plus pulse palpation and arterial pressure index… showed no clear difference in all‐cause mortality compared with pulse palpation plus arterial pressure index (ABI or TBI) (short term) (low certainty).

1 finding from 1 review

Direct thrombin inhibitors vs vitamin K antagonist (VKA)

All‐cause Mortality events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement

Direct thrombin inhibitors showed no clear difference in all‐cause Mortality events in TKR combined doses compared with vitamin K antagonists (low certainty).

1 finding from 1 review

Intramuscular injection of bone marrow mononuclear cells (BMMNC) vs control

All‐cause mortality ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy

It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes all‐cause mortality ( compared with control (very low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review